You are here: Industry Insights > SAB

News List

Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board FirstWordPharma
January 21, 2022
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease...
NEUVOGEN Appoints Mark W. Frohlich to its Board of Directors and Scientific Advisory Board firstwordpharma
August 24, 2021
NEUVOGEN, an immunoncology company, is pleased to announce the appointment of Dr. Mark W. Frohlich, MD to its Board of Directors and Scientific Advisory Board ("SAB") effective August 23, 2021.
Innovent Announces the Establishment of the Scientific Advisory Board prnasia
August 10, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced yesterday the establishment ...
SAB begins phase 1 trial of Covid-19 therapeutic candidate SAB-185 pharmaceutical-business-review
August 14, 2020
SAB Biotherapeutics, a US-based clinical-stage company, has dosed the first participant of a phase 1 study of SAB-185, its therapeutic candidate for Covid-19, in healthy volunteers.
SAB Receives $35.6 Miliion from U.S. DOD contractpharma
August 14, 2020
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human donors, has been awarded an additional $35.6 million in expanded scope for its ...
Pneumagen Appoints Scientific Advisory Board americanpharmaceuticalreview
September 03, 2019
Pneumagen announced appointments to its Scientific Advisory Board (SAB), adding expertise in the areas of respiratory disease, immunology and oncology.
Basilea Reports That Ceftobiprole Received QIDP Designation From U.S. FDA for the Treatment of Staph https://www.biospace.com/article/releases/basilea-
December 22, 2017
Basilea Pharmaceutica (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated its investigational drug ceftobiprole as a Qualified Infectious Disease Product (QIDP)